LabConnect named Tom Sellig as its new chief executive officer and a member of the board of directors.
Sellig was previously the chief commercial officer of ConnectiveRx, before which he was the senior vice president of global sales at Patheon, which was acquired by Thermo Fisher Scientific in 2017.
He also held various roles at Covance from 2007 to 2014 and had executive leadership roles at Ventana Clinical – now part of Syneos – and Medical Broadcasting Company.
"My focus at LabConnect will be on driving strategic growth, continuing to strengthen the company’s global network of clinical research labs, and providing innovative labs solutions for complex clinical studies," Sellig told us.
"Given the increase in the industry’s pipeline for advanced therapies including immuno-oncology, cell and gene therapy, and rare diseases, LabConnect is ideally positioned to manage the increased complexity inherent in these clinical programs."